Cargando…
Management of Lupus Nephritis
Lupus nephritis (LN) is a frequent and severe manifestation of systemic lupus erythematosus. The main goal of the management of LN is to avoid chronic kidney disease (CKD). Current treatment strategies remain unsatisfactory in terms of complete renal response, prevention of relapses, CKD, and progre...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916202/ https://www.ncbi.nlm.nih.gov/pubmed/33572385 http://dx.doi.org/10.3390/jcm10040670 |
_version_ | 1783657425504567296 |
---|---|
author | Tamirou, Farah Houssiau, Frédéric A. |
author_facet | Tamirou, Farah Houssiau, Frédéric A. |
author_sort | Tamirou, Farah |
collection | PubMed |
description | Lupus nephritis (LN) is a frequent and severe manifestation of systemic lupus erythematosus. The main goal of the management of LN is to avoid chronic kidney disease (CKD). Current treatment strategies remain unsatisfactory in terms of complete renal response, prevention of relapses, CKD, and progression to end-stage kidney disease. To improve the prognosis of LN, recent data suggest that we should (i) modify our treat-to-target approach by including, in addition to a clinical target, a pathological target and (ii) switch from conventional sequential therapy to combination therapy. Here, we also review the results of recent controlled randomized trials. |
format | Online Article Text |
id | pubmed-7916202 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79162022021-03-01 Management of Lupus Nephritis Tamirou, Farah Houssiau, Frédéric A. J Clin Med Review Lupus nephritis (LN) is a frequent and severe manifestation of systemic lupus erythematosus. The main goal of the management of LN is to avoid chronic kidney disease (CKD). Current treatment strategies remain unsatisfactory in terms of complete renal response, prevention of relapses, CKD, and progression to end-stage kidney disease. To improve the prognosis of LN, recent data suggest that we should (i) modify our treat-to-target approach by including, in addition to a clinical target, a pathological target and (ii) switch from conventional sequential therapy to combination therapy. Here, we also review the results of recent controlled randomized trials. MDPI 2021-02-09 /pmc/articles/PMC7916202/ /pubmed/33572385 http://dx.doi.org/10.3390/jcm10040670 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Tamirou, Farah Houssiau, Frédéric A. Management of Lupus Nephritis |
title | Management of Lupus Nephritis |
title_full | Management of Lupus Nephritis |
title_fullStr | Management of Lupus Nephritis |
title_full_unstemmed | Management of Lupus Nephritis |
title_short | Management of Lupus Nephritis |
title_sort | management of lupus nephritis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916202/ https://www.ncbi.nlm.nih.gov/pubmed/33572385 http://dx.doi.org/10.3390/jcm10040670 |
work_keys_str_mv | AT tamiroufarah managementoflupusnephritis AT houssiaufrederica managementoflupusnephritis |